6533b7d1fe1ef96bd125d866
RESEARCH PRODUCT
[Non-indicated insulin treatment].
Otto WendtBernhard KnickBernd FriedelMarie-louisa KonderPetra Nettersubject
DrugAdultmedicine.medical_specialtyEndocrinology Diabetes and Metabolismmedia_common.quotation_subjectmedicine.medical_treatmentPharmacologyBody weightInsulin doseEndocrinologyInternal medicineDiabetes mellitusInternal MedicinemedicineDiabetes MellitusHumansHypoglycemic AgentsInsulinShort durationOral therapymedia_commonAgedbusiness.industryInsulinGeneral MedicineMiddle Agedmedicine.diseaseEndocrinologyWeight Decreasebusinessdescription
171 adult- and aged-onset diabetic patients treated with insulin primarily or secondarily were subjected to an attempted therapy with the additional administration of oral antidiabetic drugs. The new potent antidiabetic drug, glybenclamide (HB 419 = Daonil), was employed on a vast scale in order to carry out an oral monotherapy in the proper indications also combined with biguanides. In the 52 % of patients in study with the additional oral therapy the insulin dose could be remarkably decreased, in the 24 % of cases insulin could be at all abolished. In another 24 % of controlled cases no decrease in insulin need was found. A body weight decrease could be obtained rather in the group of patients regulated ultimately without insulin. The success of this additional oral therapy surprisingly is not restricted to the patients with a relatively poor daily insulin need and where the insulin pre-treatment was only of a short duration.
| year | journal | country | edition | language |
|---|---|---|---|---|
| 1970-05-01 | Acta diabetologica latina |